Joseph P. Gallant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph P. Gallant has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. LeBeau
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
27 shared publications - David Kosoff
Department of Medicine University of Wisconsin‐Madison Madison Wisconsin USA
26 shared publications - Gihan S. Gunaratne
Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
26 shared publications - Jayden L. West
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
26 shared publications - Joshua Michael Lang
Carbone Cancer Center, University of Wisconsin, Madison, USA
26 shared publications - Kendahl L. Ott
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA
26 shared publications
Latest Publications
- Open Access
Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
Open AccessDevelopment of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
- Open Access
- 28 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107502
Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl
- 28 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107502
Open AccessIdentification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks